NOREPINEPHRINE BITARTRATE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.2M | 5 | 0 |
| 2020 | $1.6M | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions | Hikma Pharmaceuticals USA | $1.1M | 0 |
| Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies | Hikma Pharmaceuticals USA | $997,890 | 0 |
| "A Pivotal, Single-Dose, Open-Label, Randomized, Two-Sequence, Full Replicate Bioavailability Study of Epinephrine Nasal Spray 7 mg and Adrenalin 0.5 mg (Epinephrine Intramuscular Injection) with an Add-On Comparator Arm of Epinephrine Injection, 0.3 mg in Healthy Adults" | Hikma Pharmaceuticals USA | $567,168 | 0 |
| A Phase 1, Single-Dose, Open-Label, Randomized, Crossover, Pharmacokinetic Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.3 mg EpiPen and 0.5 mg Adrenalin) in Healthy Adults | Hikma Pharmaceuticals USA | $145,587 | 0 |
Top Doctors Receiving Payments for NOREPINEPHRINE BITARTRATE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $2.8M | 14 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.8M
- Total Doctors 0
- Transactions 14
About NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE is a drug associated with $2.8M in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2020 to 2021. In 2021, $1.2M was paid across 5 transactions to 0 doctors.
The most common payment nature for NOREPINEPHRINE BITARTRATE is "Unspecified" ($2.8M, 100.0% of total).
NOREPINEPHRINE BITARTRATE is associated with 4 research studies, including "Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions" ($1.1M).